FDAnews Drug Daily Bulletin

Dyax Strikes Deal for Chinese Sales of Drug

Feb. 8, 2013
Dyax of Burlington said it is partnering with CVie Therapeutics to develop and commercialize its drug Kalbitor in China, Hong Kong and Macau. Kalbitor is used to treat hereditary angioedema, a rare, genetic condition affecting the immune system that causes swelling of the face and airways, abdominal cramping and other angioedema indications.
Boston Herald